SCHEMBL5375384

SCHEMBL5375384

CC(O)c1cccc(CO)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
UGT2B7 P16662 1/20 0.44
ENPP2 Q13822 1/20 0.44
LMNA P02545 1/20 0.43
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
TSHR P16473 1/20 0.41
PGK1 P00558 1/20 0.41
PGK2 P07205 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PRKCI P41743 1/20 0.40
BRD4 O60885 1/20 0.39
BRD2 P25440 1/20 0.39
CREBBP Q92793 1/20 0.39
APP P05067 1/20 0.38
S1PR1 P21453 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11888529 0.85 ENPP2 (0.45) ENPP2PRSS1PRSS2PRSS3TSHR
SCHEMBL3279344 0.85 HDAC4 (0.47) ENPP2PRSS1PRSS2PRSS3TSHR
SCHEMBL26672647 0.84 TDP1 (0.45) MEN1KMT2AUGT2B7LMNAPGK1
SCHEMBL28037741 0.84 TDP1 (0.45) MEN1KMT2AUGT2B7LMNAPGK1
SCHEMBL3919972 0.83 PTGS2 (0.46) MEN1KMT2AUGT2B7LMNAPGK1
SCHEMBL19759679 0.83 ENPP2 (0.44) ENPP2PRSS1PRSS2PRSS3TSHR
SCHEMBL3919970 0.83 PTGS2 (0.46) MEN1KMT2AUGT2B7LMNAPGK1
SCHEMBL10606510 0.83 ENPP2 (0.47) ENPP2PRSS1PRSS2PRSS3TSHR
SCHEMBL23343765 0.82 ENPP2 (0.42) ENPP2PRSS1PRSS2PRSS3TSHR
SCHEMBL16952892 0.82 ENPP2 (0.42) ENPP2PRSS1PRSS2PRSS3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9987381-B2 Radioligands for imaging the LPA-1 receptor BRISTOL-MYERS SQUIBB COMPANY (US) 2018-06-05 US disclosed
US-20160256577-A1 RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR BRISTOL MYERS SQUIBB CO (US) 2016-09-08 US disclosed
EP-3062827-A1 RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR Bristol-Myers Squibb Company (US) 2016-09-07 EP disclosed
WO-2015066456-A1 RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR BRISTOL-MYERS SQUIBB COMPANY (US) 2015-05-07 WO disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160256577-A1 RADIOLIGANDS FOR IMAGING THE LPA-1 RECEPTOR LPAR1, LPAR3, LPAR2 MEN1 1354/4885KMT2A 3297/4885UGT2B7 2648/4885
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA MEN1 4860/4885KMT2A 2887/4885UGT2B7 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.